Drugs / ARO-MMP7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05537025 | Jan 2023 → Sep 2025 | idiopathic pulmonary fibrosis | Arrowhead Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-08-17 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis arrowheadpharma.com ↗
An application for approval of the clinical trial was submitted to a local Ethics Committee and to the New Zealand Medicines and Medical Devices Safety Authority for review by the Standing Committee on Therapeutic Trials. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-02-02 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis arrowheadpharma.com ↗ |
| 2022-08-17 | Arrowhead Pharmaceuticals | Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis arrowheadpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-MMP7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05537025 ↗ |
| Route | Inhaled | “ARO-MMP7 by inhalation of nebulized solution” NCT05537025 ↗ |